Literature DB >> 16822091

Review of treatments that can ameliorate nonadherence in patients with schizophrenia.

John M Kane1.   

Abstract

Nonadherence to medication is one of the major problems in treating patients with schizophrenia. Clinicians can use a variety of assessment strategies to identify patients who are nonadherent, although none of these is completely reliable. Interventions to improve adherence include psychosocial strategies, second-generation oral antipsychotics, and long-acting injectable antipsychotics. Because of the potential for reduced relapse and rehospitalization rates and the availability of second-generation antipsychotics in injectable form, a case is made for using long-acting injectable second-generation antipsychotics, when appropriate, to treat patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822091

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  27 in total

1.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

Review 2.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

Review 3.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

4.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

5.  The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country.

Authors:  Ulla A Botha; Liezl Koen; John A Joska; John S Parker; Neil Horn; Linda M Hering; Piet P Oosthuizen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-06-18       Impact factor: 4.328

6.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

7.  Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla).

Authors:  Ulrike Stentzel; Neeltje van den Berg; Lara N Schulze; Thea Schwaneberg; Franziska Radicke; Jens M Langosch; Harald J Freyberger; Wolfgang Hoffmann; Hans-Jörgen Grabe
Journal:  BMC Psychiatry       Date:  2018-05-29       Impact factor: 3.630

8.  Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Rosario de Arce Cordón; Evelin Eding; Joao Marques-Teixeira; Vihra Milanova; Elmars Rancans; Andreas Schreiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-02       Impact factor: 5.270

9.  Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.

Authors:  Rosaria Di Lorenzo; Alice Brogli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 10.  Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Authors:  Matt Shirley; Caroline M Perry
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.